HIV Studies

Collaborative Clinical Trials

AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

Diseases Treated:

HIV Infection

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • The subject has been enrolled on IMPAACT P1025.
View Trial

ATN129: Comparing the Effectiveness of Two Alcohol+Adherence Interventions for HIV+ Youth

Diseases Treated:

HIV

Eligibility:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • Participant receives services at St. Jude.
  • Participant has HIV-1 Infection.
  • Participant is between the ages of 16 years and 24 years.
  • Participant has been offered a prescription for antiretroviral (ARV) medications.
  • Participant is able to understand, read, and speak English.
  • Participant has used alcohol in the last 12 weeks prior to screening.
View Trial

ELVIS: Two Part Study to Study Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir (EVG) Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Subjects

Diseases Treated:

HIV Infection

Eligibility:

  • Participant does not have life expectancy of less than 1 year.
  • Participant does not have history of significant drug sensitivity or drug allergy.
  • Participant is not participating in any other clinical trial without prior approval from sponsor while participating in this trial.
  • Participant does not have an ongoing serious infection requiring systemic antibiotic therapy at the time of screening.
View Trial

GS1269: Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Adolescents Virologically Suppressed on a 2-NRTI-Containing Regimen

Diseases Treated:

HIV/AIDS

Eligibility:

  • Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline.
  • Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening.
  • Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening.
View Trial

P1093: Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents

Diseases Treated:

Human Immunodeficiency Virus

Eligibility:

  • At least 4 weeks old but younger than 18 years old
  • Confirmed HIV-1 infection
  • Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.)
View Trial